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Abstract Resistant Hypertension (RH) is a clinical condition in which the hypertensive patient 
has become resistant to drug therapy and is often associated with increased cardiovascular 
morbidity and mortality. Several signaling pathways have been studied and related to the 
development and progression of RH: Modulation of sympathetic activity by leptin and 
aldosterone, primary aldosteronism, arterial stiffness, endothelial dysfunction and variations in 
the renin-angiotensin-aldosterone system (RAAS). MicroRNAs (miRNA) comprise a family of 
small noncoding RNAs that participate in the regulation of gene expression at post-
transcriptional level. miRNAs are involved in the development of both cardiovascular damage 
and hypertension. Little is known on the molecular mechanisms that lead to development and 
progression of this condition. This review aims to cover the potential roles of microRNAs in the 
mechanisms associated with the development and consequences of RH, and explore the current 
state of the art of diagnostic and therapeutic tools based on microRNA approaches. 
Keywords MicroRNA; Resistant Hypertension; Signaling Pathways  
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Abbreviations List  
20-HETE - 20-hydroxyeicosatetraenoic acid 
ABPM - ambulatory blood pressure monitoring  
ACE - angiotensin converting enzyme  
ADMA - asymmetric dimethylarginine 
AGT - angiotensinogen  
ALLHAT - antihypertensive and lipid-lowering treatment to prevent heart attack trial 
AngI - angiotensin I  
AngII - angiotensin II  
APCs - angiogenic progenitor cells  
AT1 - angiotensin 1 receptor  
AVPR1A - arginine-vasopressin receptor  
Bcl-2 - B-cell lymphoma 2 
BDKRB2 - bradykinin β2 receptor  
bFGF - basic fibroblast growth factor 
BP - blood pressure  
CAV1 - Caveolin-1  
COX-2 - cyclooxygenase-2  
CYP4A - cytochrome P450-4A) 
EGF - epidermal growth factor 
EGFR - Epidermal growth factor receptor 
eNOS - endothelial NO synthase  
ERK - extracellular regulated kinase 
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ET-1 - endothelin-1 
FOXO1 - forkhead box 1 
FoxO1 - forkhead Transcription factor 
GATA2 - endothelial transcription factor GATA2 
GLUT4- glucose transporter 4 
GPCRs - G-protein-coupled receptors 
HDL - High density lipoprotein cholesterol 
LNA - locked-nucleic-acid  
MAPKs - mitogen-activated protein kinases  
MCP-1 - monocyte chemoattractant protein-1  
MEK - mitogen-activated protein kinase 
miRNA – microRNAs 
MMP - matrix metalloproteinase 
mTOR - mammalian target of repamycin  
NO - nitric oxide  
NYHA - New York Heart Association  
PAK4 - serine/threonine-protein kinase PAK4 
PDGF - platelet-derived growth factor 
PG - prostaglandins  
PI3K - phosphoinositide 3-kinase  
PIK3R2 - phosphoinositide-3-kinase regulatory subunit 2 
PIP3 - phosphatidylinositol 3,4,5-trisphosphate  
PKC - protein kinase C  
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PLC - phospholipase C  
PLD - phospholipase D  
pri-miRNA - primary miRNAs 
RAAS - renin-angiotensin-aldosterone system 
RH - resistant hypertension 
RhoB - ras homolog family member B  
RISC - RNA-induced silencing complex 
ROS - reactive oxygen species 
RTKs - receptor tyrosine kinases 
S1P - sphingosine-1-phosphate 
SirT1 - silent information regulator 1 
SNS - Sympathetic nervous system 
Spred-1 - Sprouty-related protein  
SRF - Serum Response Fator  
TBXA2R - thromboxane A2 receptor 
VCAM1 - vascular cell adhesion molecule 1  
VEGF - vascular endothelial growth fator  
VSMC - vascular smooth muscle cells  
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1.Introduction 
Resistant Hypertension 
Resistant hypertension (RH) is characterized by a condition in which the patient 
requires four or more antihypertensive medications, including a diuretic, regardless 
blood pressure control. RH patients can be classified as controlled or uncontrolled 
according to the achievement of the blood pressure goals (1).  
The RH affects approximately 13% to 25% of the hypertensive population (2-
4)and represents a risk factor for cardiovascular events. Results from the 
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
(ALLHAT) showed increased hazard ratios for stroke (1.57), end-stage renal disease 
(1.95), heart failure (1.88), coronary heart disease (1.44) and all-cause mortality (1.30) 
in RH compared to non-resistant hypertensive subjects(5).  
RH is a multifactorial condition and several environmental and genetic factors 
contribute to the development and progression of the disease. Firstly, the identification 
of pseudoresistence must be performed to identify true resistant hypertensive patients, 
caused mainly due to poor BP measurements, lack of adherence, suboptimal therapy 
and white coat hypertension. In addition, secondary causes of RH, such as primary 
aldosteronism, pheochromocytoma, renal artery stenosis or Cushing’s syndrome should 
be identified since the pharmacological treatment will be specific for each condition. 
Among the factors associated with an increased risk for RH are: older age, African 
origin, female gender, overweight and obesity (1, 6). 
The RH present three relevant characteristics: 1) high incidence of the following 
comorbidities: obstructive sleep apnea (7), thyroid disorders (7), primary aldosteronism 
(8, 9), reduced plasmatic renin activity, obesity (6), diabetes mellitus (1, 6) 2) high 
prevalence of target organ damage; and 3) high blood pressure (BP) levels measured by 
ambulatory blood pressure monitoring (ABPM) (10-12). 
The achievement of the BP goals relies on physician examination and on patient 
characteristics and compliance to pharmacological and non-pharmacological treatments. 
It is well know that obesity, excessive alcohol and/or salt intake, sedentary lifestyle, 
smoking, insulin resistance, difficulty in adopting dietary measures and lack of 
adherence to therapeutic treatment affects BP control (12). In addition, prescription of 
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high-cost medicines by physicians, multiple administration regimens, suboptimal doses 
and presence of adverse effects  are associated with uncontrolled BP (13). 
The factors associated with diagnostic and treatment of  RH, including  lifestyle, 
detailed history of medication adherence, correct BP measurement, biochemical 
analysis for dosage of electrolytes, glucose and creatinine, as well as determination of 
protein and sodium in the urine (12). 
It is also necessary the exclusion of pseudohypertension. For example, 
Mönckeberg’s sclerosis is a condition characterized by the loss of elasticity and 
thickening of the walls of the muscular arteries caused by a calcification of the tunica 
media constituted of smooth muscle. In the measurement of blood pressure by non-
invasive methods, the patient presents high BP values, while in reality it pressure is 
normal, therefore, it is necessary to use invasive measurement methods to correctly 
measure it BP (12). White coat hypertension, also a condition of pseudoresistance, 
where the patient exhibits high values during the verification in the physician’s office. It 
can be excluded by 24 hours ABPM. It is estimated that 30% of patients with elevated 
BP and with treatment of up to 3 drugs present this condition of white coat hypertension 
(12, 14). 
In order to complete the diagnosis of RH, there are some clinical situations that 
are considered as secondary causes of this condition, such as: primary 
hyperaldosteronism, pheochromocytoma, fibromuscular dysplasia, patients with 
increased risk of atherogenesis (12), obstructive sleep apnea, renal artery stenosis, renal 
parenchymal disease, Cushing's syndrome, and thyroid and parathyroid diseases (10). 
These forms of secondary hypertension present high prevalence in association with RH, 
as can be verified in table 1.Hyperaldosteronism results from the excessive production 
of aldosterone, a hormone that is produced in the adrenal glands and that decreases the 
excretion of sodium and increase the excretion of potassium by the kidneys, sweating, 
and saliva. The determination of the rate of aldosterone/renin ratio is used as screening 
tool for hyperaldosteronism diagnostic, and if any alteration is confirmed, diagnostic 
imaging and blood samples from each side of the adrenal glands are used to corroborate 
the diagnosis (12).Obstructive sleep apnea consists of the collapsing of the pharynx 
walls hampering the adequate respiration of the individual. The patient is then submitted 
to a nocturnal polysomnography in order to monitor respiration and body functions 
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duringsleep for diagnostic of the condition (15). For more information on diagnostic and 
treatment methods, see table 1 (14) .  
A flowchart (Figure 1) summarizes the steps involved in the diagnostic of RH 
according to the American Heart Association Statement (1, 16). 
[TABLE 1] 
[FIGURE 1]  
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 Although RH is a multifactorial condition, sodium excess, fluid retention, 
increased activation of the Renin Angiotensin Aldosterone System and higher 
sympathetic tone are among the most well-described mechanisms of BP elevation in 
RH. The complex pathophysiology of the development and progression of RH requires 
further investigation to identify molecular mechanisms that could be translated into 
diagnostic and more assertive therapeutic strategies. In the following sessions, the 
signaling pathways and the participation of miRNA in their regulation will be discussed.  
 
2. Renin Angiotensin Aldosterone System 
 The Renin-Angiotensin-Aldosterone System (RAAS) is responsible for the 
hemodynamic equilibrium. This is possible due to the effects of this system on the 
kidneys, that act in the sodium water balance, and also due to the influence in the 
vascular resistance on the peripheral blood vessels, thus permitting the maintenance of 
the BP (17). In order to the RAAS to produce a response it is necessary that occur some 
type of alteration in the circulating blood volume, such as blood loss, dehydration or 
even pumping failure by the ventricles (18) (Figure 2).  
Juxtaglomerular apparatus comprises afferent arterioles in the distal part of the 
ascending branch of the loop of Henle in the renal glomeruli. The cells that line these 
arterioles in the region of the apparatus are called juxtaglomerular cells and are able to 
recognize the BP inside these vessels (18). Moreover, the cells that line the loop of 
Henle in the region of the juxtaglomerular apparatus are called macula densa and 
respond to changes in the sodium concentration of the filtrate. By detecting these 
changes, the cells of the dense macula stimulate juxtaglomerular cells to produce an 
enzyme called renin that is released into the bloodstream. This enzyme is responsible 
for the production of angiotensin I (AngI) through the cleavage of angiotensinogen, 
which is synthesized and secreted by the liver. In the pulmonary and renal endothelium, 
an enzyme called angiotensin converting enzyme (ACE), which hydrolyzes the 
circulating AngI in angiotensin II (AngII), is present. The angiotensin 1 receptor (AT1) 
is activated by AngII thus promoting a vasoconstrictive response in the blood vessels, in 
addition to stimulating the adrenal gland to produce aldosterone. The renal tubules 
respond to the aldosterone by retention of sodium and water, which will promote 
increased blood volume and consequently, BP elevation (19, 20). 
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[FIGURE 2] 
 
The RAAS constitutes the main signaling pathway involved in the long-term 
control of the BP. Innumerous regulators participate in this biochemical cascade of 
communication such as renin, angiotensinogen, AngI and II, ACE 1 and 2, aldosterone 
and angiotensin- (1-7) [Ang- (1-7)]. The deregulation of one or more effectors of this 
system contributes to failures in blood pressure control, usually leading to hypertension 
(21). Resistant Hypertension is accompanied by intravascular fluid retention that can be 
attributed, at least in part, to dysregulation in the renin-angiotensin-aldosterone system. 
Previous studies have found evidence of intravascular volume expansion (higher levels 
of brain-type natriuretic peptide – BNP, and atrial natriuretic peptide - ANP) and 
aldosterone excess (higher levels of plasma and urinary aldosterone, aldosterone to 
renin ratio) in resistant hypertension compared to controls (22). Similarly, another study 
reported higher volume of fluid by thoracic electrical bioimpedance, sugesting that the 
intensificaton of diuretic thereapy in those patients could be beneficial (23). ANP and 
BNP are hormones that regulate cardiovascular hemodynamics. They are secreted by, 
respectively, cardiac atria and cardiac ventricles, in response to stretch or pressure. 
Natriuretic effects are mediate by subtype A-natriuretic peptide receptor, which is 
expressed in several tissues, including kidneys, blood vessels, adrenal glands, and 
adipose tissue. ANP produces its natriuretic actions by increases glomerular filtration 
rate, inhibits sodium transport in proximal tubule and inhibition of aldosterone release 
in adrenal cells. The latter effect is also attributed to BNP (24). Aldosterone is one of 
the most studied RAAS components in RH, several studies had shown that aldosterone 
excess is a common characteristic of RH. In addition, primary aldosteronism is the most 
common secondary cause in the patients with RH (8). This condition is characterized by 
excessive autonomic secretion of aldosterone by the adrenal gland, being the production 
of adenomas and idiopathic hyperaldosteronism the main forms (32, 33). This secretion, 
stimulated by renin, promotes the retention of sodium and water, promoting the 
elevation of blood volume, and consequently the increase of BP. When it is released 
into the bloodstream, the aldosterone diffuses through the membrane into the cytosol of 
renal tubular epithelial cells, subsequently binding to a family of NRC2-type 
mineralocorticoid receptors. This aldosterone-receptor complex will be translocated to 
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the nucleus, activating the synthesis of proteins related to sodium and potassium 
transport, such as Na
+
 K
+
 ATPase (Figure 3) (25). 
 
[FIGURE 3] 
 
An important signaling pathway in the primary aldosteronism is the PI3K 
(phosphoinositide 3-kinase) pathway with the activation of mTOR (mammalian target 
of repamycin), when overactivated is involved in the tumorigenesis and metastasis in 
some types of human tumors such as renal cancer, adrenal carcinoma and 
pheochromocytoma (26-28) (Figure 4) (27). The PI3K/AKT/mTOR pathway is 
regulated in response to the signaling of growth factors such as the epidermal growth 
factor (EGF) through receptor tyrosine kinases (RTKs)(29). 
Another stimulus to the release of aldosterone is the action of sphingosine-1-
phosphate (S1P) by means of the activation of the PI3K/AKT (protein kinase B) and 
MEK (mitogen-activated protein kinase)/ERK (extracellular regulated kinase) pathway 
in glomerular cells of the adrenal glands (Figure 4) (28). S1P is a bioactive sphingolipid 
intracellularly formed that acts as a second messenger mediating regulatory processes 
such as cell differentiation, migration and contraction, modulation of immune response 
and angiogenesis, and this molecule is considered to be the key hormone for 
hemodynamic stability in humans (30, 31). Its action involves the activation of 
phospholipase D (PLD), calcium influx (Ca
2+
) from the extracellular medium and 
phosphorylation of α and β isoforms of protein kinase C (PKC) (30, 32, 33). 
 
[FIGURE 4] 
 
Previous studies had shown excess of aldosterone in uncontrolled RH compared 
to controlled group. The same study demonstrated that aldosterone was correlated to 
arterial stiffness (34). Furthermore, higher aldosterone levels were associated with the T 
allele for the polymorphism -344 C/T CYP11B2 (aldosterone synthase gene) in RH 
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subjects, and this effect was shown to be more pronounced in patients under 
spironolactone treatment (35). Studies have demonstrated significant reductions in 
blood pressure with addition of mineralocorticoid receptors antagonists, such as 
spironolactone, and that drug has been suggested as the optimal fourth-line drug for BP 
control in RH (159). 
 Angio-(1-7) is a heptapeptide that carries out an important function in the 
RAAS. This molecule is formed both by the action of ACE 1 (dependent pathway) and 
the hydrolysis of AngII by the ACE 2 (independent pathway) (36, 37) being this last 
one the most important pathway in the formation of Ang-(1-7) (38). This molecule 
produces its AngII endogenous counter-regulatory effects on RAAS (vasodilation, 
cardio protection, natriuresis and diuresis, angiogenesis inhibition, and cellular growth) 
(39) through the binding to its specific receptor called Mas, a G protein-coupled 
receptor (32, 40, 41). 
The ACE2/Ang-(1-7)/Mas signaling pathway consists in one of the RAAS axes 
that opposes, in terms of function, to another classical axis of this system, the 
ACE/AngII/AT1R. The imbalance of these two opposing axes, mainly in the direction 
of the ACE/AngII/AT1R axis predisposes to cardiovascular diseases and other disorders 
(37, 41). 
The Ang-(1-7)/Mas complex regulates different signaling pathways, such as 
PI3K/AKT and ERK signal, and involves the maintenance of some effectors like nitric 
oxide (NO)(32, 41), FOXO1 (forkhead box 1)(39) and cyclooxygenase-2 (COX-2)(40) 
(Figure 5). Studies report that due to the participation of the Ang-(1-7) in these 
mechanisms, this heptapeptide is related to pathological conditions such as fibrosis and 
inflammatory processes in some organs, like lungs, liver and kidneys (42). Other 
findings demonstrate that Ang-(1-7), through the interaction with its Mas receptor, 
stimulates the activation of the nitric oxide synthesis (eNOS) in endothelial cells, 
promoting vasodilation (32, 36, 41). 
Another study demonstrates that Ang-(1-7), through the interaction with its 
specific Mas receptor promotes the increase of nitric oxide (NO) and prostaglandins 
(PG) synthesis and release leading to vasodilation and inhibition of cellular growth, 
opposing to the vasoconstrictor and proliferative effects mediated by the interaction of 
AngII with its AT1 receptors. The imbalance between these two axes of the RAAS, 
13 
 
reflected by the imbalance between theses peptides, which are observed in 
cardiovascular diseases, can lead to the decrease of NO and consequently to endothelial 
dysfunction (Figure 5) (43). 
 
[FIGURE 5] 
 
2.3. Sympathetic Nervous System  
Sympathetic nervous system regulates cardiac output and peripheral vascular 
resistance (vasoconstriction) through release of norepinephrine and epinephrine, 
resulting in increase in blood pressure. At the renal level, SNS activation increases renin 
release from juxtaglomerular cells and modulate tubular sodium reabsorption (44). RH 
patients have reduced heart rate variability, which is a marker for SNS activity. It was 
shown that 63% of the patients present a nondipping pattern (BP do not drop at night), 
which indicate sympathetic overflow. Moreover, sympathetic activation also increase 
sodium reabsorption and promote renin secretion and renal denervation has been 
investigated for treatment of resistant hypertension. In spite first studies in humans had 
shown promising results, randomized and blinded clinical trials demonstrated no benefit 
on BP control compared to sham procedure (45). Another intervention that has been 
tested is baroreflex activation therapy. Carotid sinus stimulation reduces BP in patients 
with uncontrolled RH, showing the import role of sympathetic activity in this condition 
(46-48). 
 
2.4 - Adipokines 
14 
 
 Adiponectin and leptin are two of the adipokines produced in adipose tissue. 
Obesity is an important comorbidity in RH and plasma levels of adiponectin and leptin 
were reported to be lower and higher, respectively in RH (34) (49). Leptin is a peptide 
hormone that is expressed in a variety of tissues, such as lymphoid tissue, pituitary 
gland, skeletal muscle, placenta, and ovary (50). However, white adipose tissue is the 
main responsible for the synthesis and secretion of this peptide, which has as effects to 
act on the hypothalamus in order to decrease appetite and stimulate sympathetic activity 
of the nervous system (Figure 6) (51). Elevated levels of leptin stimulate neurons in the 
hypothalamus to secrete a precursor protein that is cleaved in α-melanocyte stimulating 
hormone, which binds to melanocortin 3 and melanocortin 4 receptors. The binding of 
this peptide to the receptors stimulates the sympathetic nervous system, elevates the 
energy expenditure, decreases food intake, and activates the hypothalamic-pituitary-
adrenal axis (52-54). A mechanism that demonstrates which factors are involved in the 
generation of hypertension associated with obesity is represented below (Figure 6) (51). 
 
[FIGURE 6] 
 
2.5. Insulin resistance and hypertension: the role of the Caveolin-1 (CAV1) gene 
It was recently demonstrated that the gene Caveolin-1 (CAV1), located in the 
chromosome 7q31.1 (55) constitutes a gene that is associated with metabolic 
dysfunction in animal and cellular models, especially in insulin resistance, proving to be 
a potential marker for this condition in human beings (56). Genetic variations in CAV1 
are involved in the mechanism of insulin signaling and vascular function (Figure 7), 
shown in studies with animal models and cell culture (57, 58). 
Increase in homeostasis model assessment of insulin resistance (HOMA-IR), 
showing that CAV1 is not only a genetic marker for dysfunction but also provides 
information about a potential mechanism of development of insulin resistance and 
hypertension in humans (56).  
CAV1 is a regulatory gene for insulin signaling and insulin receptor stability 
(56). Specifically, CAV1 binds directly to the insulin receptor in the adipocytes and the 
disturbance of this complex by GM3 ganglioside causes alteration in insulin signaling 
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(59) (Figures 7 and 8). In addition, the decrease in CAV1 activity results in a 90% 
reduction in insulin receptor levels in the adipocytes of knockout rats (60). 
Although the role of CAV1 in insulin-mediated glucose uptake is not well 
elucidated (60), this gene demonstrated relevance in the translocation of glucose 
transporter 4 (GLUT4) to adipocyte (61) and muscle cells (62). 
 
[FIGURE 7] 
 
[FIGURE 8] 
 
 
2.6 Vascular stiffness and endothelial dysfunction 
Previous studies has been showed the participation of vascular stiffness and endothelial 
dysfunction in the pathogenesis of resistant hypertension. An increased carotid-femoral 
pulse wave velocity was observed in RH patients compared to non RH hypertension, 
demonstrating the impairment of elasticity in these vessels. In addition, flow-mediated 
dilation was found to be reduced in RH, reflecting an endothelial dysfunction (63). 
2.6.1 Epidermal growth factor receptor in the vascular smooth muscle 
The activation of the signaling pathway of the EGFR by matrix 
metalloproteinase (MMP), stimulated by GPCR agonists, such as catecholamines, 
endothelin-1 (ET-1) and AngII lead to the increase of the oxidative stress, promote 
stimulation of the hypertrophic growth and consequently increase of the muscular tone 
in hypertension (Figure 9) (64). Among these receptors it can be mentioned 
adrenoceptors and angiotensin receptors that contribute to the hypertension 
pathogenesis mainly through the vasoconstrictor effects produced after stimulation (65, 
66).   
The vasoconstrictor responses promoted by this pathway are mediated by 
phospholipase C (PLC), DAG and Ca
2+
 besides the growth promotion pathway 
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involving the tyrosine receptor and mitogen-activated protein kinases (MAPKs) (Figure 
9) (67). Studies have shown a connection between the GPCR stimulus with the MAPK 
signaling pathway (through the dependent activation of MPM) in the vascular smooth 
muscle cells (65, 68-70). Associations have been made between GPCR stimulus by 
MPM’s such as MPM-2, MPM-3, and MPM-7 in cardiomyocytes, fibroblasts and 
epithelial and endothelial cells (71) with consequent development of cardiovascular 
hypertrophy associated with hypertension (72-75). 
[FIGURE 9] 
 
2.6.2 CYP4A (cytochrome P450-4A)/20-HETE (20-hydroxyeicosatetraenoic acid) 
 20-HETE is an arachidonic acid metabolite formed through reactions catalyzed 
by the cytochrome P450-4A enzymatic complex (CYP4A) in vascular smooth muscle 
cells and is related to vascular dysfunction and arterial hypertension (Figure 10) (76). 
This molecule has vasoconstrictive action and exerts an important role in vascular 
function and in the development and progression of cardiovascular diseases (77). 
Studies have demonstrated the relationship between genetic variations in precursors of 
20-HETE formation and the elevation of this metabolite and the BP in humans (78, 79). 
In Dahl SS (salt-sensitive) rats, a genetic model of salt-sensitive hypertension, 
20-HETE has been shown to contribute to the increase of total peripheral resistance by 
reducing the ability of the vascular system to respond to direct vasodilation stimulation 
by reducing vascular function, thus contributing to an increase in BP (80, 81). 
 Some studies demonstrate that ROS (reactive oxygen species) are important 
molecules in the development of oxidative stress, playing an important role in vascular 
dysfunction in Dahl SS rats (82, 83). The chronic exposure to low levels of AngII in 
these animals may lead to an increase in oxidative stress by elevating ROS cellular 
concentrations, thus contributing to the reduction of vascular relaxation even when these 
animals are submitted to a sodium restriction diet or are normotensive (84). 
 
[FIGURE 10] 
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3. MicroRNAs  
MicroRNAs (miRNA) are members of a class of small non-coding RNAs that 
are able to interfere with the translation of several genes (85). They are highly 
conserved molecules present in many s species and components of the miRNA 
synthesis machinery can be found in bacteria and species of archaea scattered (86). The 
miRNAs are single stranded molecules formed of approximately 22 nucleotides, 
generated from endogenous transcripts (86), expressed from intergenic regions or from 
introns. The biogenesis of miRNA begins in the nucleus from long precursors called 
primary miRNAs (pri-miRNA) transcribed by polymerase II (87). The pri-miRNAs, 
still in the nucleus, are processed by Drosha and its cofactor DGCR8 (88, 89), that 
remove a region of the double-stranded ribbon and flanking sequences resulting the pre-
miRNAs. The pre-miRNAs are transported to the nucleus via Exportin-5 (90). In the 
cytoplasm, the pre-miRNAs are cleaved by a ribonuclease III, called Dicer, forming the 
mature miRNAs (91). The mature miRNA associates to a complex of enzymes called 
RISC and acts on the translation of mRNA according to the complementarity between 
the miRNA and its target (92, 93) (Figure 11). A complete pairing between the miRNA 
and its target causes cleavage of the mRNA while an incomplete pairing causes the 
silencing of the target mRNA expression (94). 
The miRNAs are among the most abundant gene regulatory molecules (95) and 
participate in important regulatory cell pathways, such as apoptosis, cell proliferation, 
differentiation and development (96-98), and also in various cardiovascular conditions 
such as cardiac hypertrophy, arrhythmias, apoptosis, and regeneration of 
cardiomyocytes, fibrosis, heart failure (99), coronary heart disease, acute myocardial 
infarction (100) and essential hypertension (101). 
Besides, miRNAs are currently considered as new hormones or molecules that 
carry information through intercellular mechanisms. they can be transported by body 
fluids, such as blood, serum, urine, breast milk, circulating extracellular vesicles, 
exosomes and microvesicles, in addition to complexes with particles of HDL, protected 
from degradation by RNAses and other enzymes (102), thus being characterized as 
potential molecular biomarkers for disease prognosis or as a predictor of therapeutic 
efficacy (103). 
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[FIGURE11]
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3. 1. miRNAs involved in hypertension  
Due to the difficulty of studying RH in animal and in vitro models, the studies 
are clinical and poorly understood in terms of mechanisms. Thus, we decided to 
describe the microRNAs that interact with the most relevant pathways in RH. To date, 
several miRNAs have been identified and are related to the complications of resistant 
hypertension (Figure 12). The most important are listed below (Table 2): 
[TABLE 2] 
1. RAAS 
 
The miRNAs miR-181a and miR-663 appear to be directly related to the 
hypertensive condition. Patients with untreated hypertension demonstrated a low 
expression of miR-181a and miR-663 in kidney samples. Experiments in culture 
demonstrated that miR-181 and miR-663 were able to regulate renin expression. The 
data show that the low expression of these two miRNAs causes the elevation of the 
renin expression leading to the hypertensive condition (104). In addition, the presence 
of miR-181a in the serum of hypertensive patients was verified. Little is known about 
the role of miR-181a in the control of renin or whether there are other targets in the 
kidney. Future work should focus on the regulatory role of miR-181 over the other 
components of RAAS (105).   
The expression of AT1R (angiotensin II type I receptor) and AT2R (angiotensin 
II type 2 receptor) are regulated mainly by post-transcriptional mechanisms. It was 
verified that miR-155 (expressed in fibroblasts and VSMCs) and miR-802 (expressed in 
intestinal epithelial cells), in functional assay, are responsible for the repression of 
AT1R expression, not by decreasing levels of mRNA, but by blocking mRNA 
translation. Consequently, it leads to the reduction of activation of Angiotensin II-
induced ERK1/ERK2 signaling pathway (106-108). Li et al. demonstrated the existence 
of a pattern of expression of miRNAs in the plasma of hypertensive patients when 
compared with controls. In this study, an increase in the expression of miR-296-5p, let-
7e, hcmv-miR-UL1 and hcmv-miR-UL112 was verified, which acts via IRF-1 (109). 
There are evidences that the IRF-1 transcription factor up-regulates the AT2R and plays 
a role in angiogenesis, neointima formation, endothelial function and SMC migration 
(109).  
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An imbalance in the angiotensin II signaling pathway may lead to hypertensive 
condition. miR-483-3p is a VSMC-specific miRNA and demonstrates to be a general 
regulator of RAAS, since several components of this system contain the target sequence 
for this miRNA. Experiments in cell culture proved that this miRNA acts by 
suppressing the protein levels of angiotensinogen (AGT), angiotensin I converting 
enzyme (ACE-1), angiotensin II converting enzyme (ACE-2) and AT2R without altering 
the levels of its transcripts (110). 
Reports show that miR-132 and miR212 are involved in angiotensin II-induced 
hypertension. Hypertensive rats show elevated expression of miR-132 and miR-212 in 
the heart, aortic wall, kidneys and plasma after 10 days of sustained hypertension by 
angiotensin II infusion. The treatment of hypertensive patients with AT1R receptor 
blockers exhibits a lower expression of miR-132 and miR-212 confirming their 
influence on the hypertension phenotype. miR-132 and miR-212 act by activating the 
Gαq/ ERK1/ 2 signaling pathway (111). In a case-control study, 9 single nucleotide 
polymorphisms (SNPs) were genotyped in 7 RAAS-related genes with a common site 
of miRNA recognition in the 3'-UTR region of the mRNA of these genes. In order to 
verify the functionality of each SNP in the mRNA/miRNA interaction a dual-luciferase 
reporter gene was used. Four SNPs located in genes associated with blood pressure 
were reported: the gene coding the arginine-vasopressin receptor (AVPR1A), the gene 
coding the bradykinin β2 receptor (BDKRB2), and the gene coding the thromboxane A2 
receptor (TBXA2R) (112). 
Nossent et al. demonstrated that rs11174811 SNP in AVPR1A interferes in the 
interaction of this gene with miR-526b and miR -578 and, as a consequence, there is an 
increase in the expression of vasopressin receptor (112) causing an increase in blood 
pressure. rs5225 and rs2069591 SNPs in BDKRB2 interfere in the interaction of these 
genes with miR-34a and miR-34c, culminating in an increase of this receptor 
expression, consequently inducing vasodilation and inhibiting re-uptake by aquaporin.  
miR-151-3p inhibits the expression of the bradykinin receptor interacting with the 
rs2069591 SNP located in the PTK2B gene which, in turn, has its vasopressin 
expression stimulated. miR-765 interacts with rs13306046 SNP of thromboxane A2 
receptor, a potent vasoconstrictor, causing an inhibition of the expression of this 
receptor and a consequent decrease in blood pressure. miR-383 has been associated with 
increased risk of myocardial infarction but is not associated with the increase in blood 
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pressure. This miRNA acts on the rs5534 SNP repressing the NR3C2 gene coding the 
mineralocorticoid receptor (aldosterone receptor) (112). 
In the same way, the polymorphisms encountered in the 3'UTR region of 
SLC7A1 mRNA (solute carrier family 7 member 1), which has more or less sites for 
miR-122 binding causing a differential expression of it, leading to hypertension 
phenotype with endothelial dysfunction with decrease of nitric oxide and L-arginine 
metabolism phenotype (113-115). 
The miRNA 24 is expressed in the adrenal cortex and regulates the production of 
aldosterone and cortisol, since it binds to the 3'UTR region of the mRNAs CYP11B1 
(11β-hydroxylase) and CYP11B2 (aldosterone synthase) which repress them, leading to 
the decrease in the production of these hormones. Deregulation of production may lead 
to hypertension. This same miRNA is expressed in cells in the lung where hypoxia leads 
to the increase of miR-24 expression and the activation of smooth muscle cells (116). 
Intracellular raise of miR-24 leads to diminished expression of the GATA2 (Endothelial 
transcription factor GATA2) and PAK4 (Serine/threonine-protein kinase PAK4) 
transcription factors with functions defined in vascular biology (117) and its inhibition 
induces the increase of angiogenesis (118). 
In experiments with luciferase it was proved that miR-124 and miR-135a are 
associated with hypertension and they interfere on expression of the nuclear receptor of 
subfamily 3, group C, member 2 (NR3C2), an aldosterone receptor that participates in 
the control of blood pressure by promoting the retention of salt by the kidney. miR-124 
and miR-135a reduce the protein expression of NR3C2, contributing to the modulation 
of aldosterone signaling in RAAS, reflecting in the control of blood pressure (119). 
miR-584 and miR-31 are predicted to act in a 3'UTR region on 11525C SPN  in 
the human angiotensinogen (AGT) gene. In a cell culture study, the transfection of these 
miRNAs reduced the levels of AGT expression. Patients that presented 11525A SNP of 
AGT gene have higher plasma and tissue AGT levels, and consequently increased blood 
pressure due to the lower interaction of this gene with miR-584 and miR-31 when 
compared to patients with 11525C SNP (120). 
Studies show that miR-145 and miR-143 are essential for differentiation (121) 
and modulation of vascular smooth muscle cells (VSMC), since the elimination of Dicer 
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in these cells causes profound hypotension, reflecting in vivo contractile dysfunction, 
blood pressure regulation defects, and vascular remodeling (122). miR-143 and miR-
145 demonstrated a relationship to the fate of the VSMCs and maintenance of 
contractility since KO rats for these two miRNAs exhibit a phenotype that is similar to 
the rats in which Dicer was eliminated. In addition to this, the overexpression of miR-
145 in KO animals for Dicer regains vessel contractility (122). 
Boettger et al. demonstrated that the expression of miR-143 and miR-145 during 
mouse development is essential for the contractile phenotype of VSMC (123). Xin et al. 
showed that the Serum Response Factor (SRF) controls the expression of miR-143 and 
miR-145 in VSMC and the absence of these miRNAS causes an imbalance in the 
feedback cycles needed for the cytoskeleton homeostasis in the VSMC compromising 
the contractile phenotype of these cells (124). miR-145 acts by suppressing ACE and, in 
this way, by controlling the stimulation of angiotensin II in VSMCs, thus contributing to 
the preservation of its contractile phenotype and maintenance of normal blood pressure 
(123).   
miR-143 and miR-145 knockout rats, the actin stress fibers are in disorder, 
compromising the migratory activity of VSMCs (124), which impair the formation of 
neointima in response to vascular injury and overregulates (121) the ACE in VSMC 
(123). There are evidences that these miRNAs are closely involved in the phenotypic 
reversion of VSMCs during hypertension (121). 
In hypertensive patients, miR-9 levels are significantly inferior compared to 
normotensive patients (125). miR-9 is reported to be a negative regulator of cardiac 
hypertrophy (126) through inhibition of myocardin. Myocardin is a protein that is found 
in elevated expression in patients with cardiac hypertrophy and activated by the binding 
of nuclear factor of activated T-cells c3 (NFATc3) to its promoter region (126).  
mir-126 is highly expressed in hypertensive patients (138), which favors 
angiogenesis and vascular integrity in vivo (127, 128). Studies have shown a correlates 
between miR-126 and Sprouty-related protein (Spred-1) repression (127, 128). Spred-1 
interacts and inactivates RAF1 negatively regulating the signaling of the Vascular 
endothelial growth factor (VEGF) through MAP kinase, by repression of the 
phosphoinositide-3-kinase regulatory subunit 2 (PIK3R2), a negative regulator of PI3K, 
another pathway activated by the signaling of the VEGF and with vascular cell adhesion 
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molecule 1 (VCAM1) repression, limiting the adherence of leucocytes to the endothelial 
cells (129). 
miR-21 is significantly upregulated in hypertension (130) and unlike miR-126, 
miR-21 acts as a negative modulator of angiogenesis inhibiting the proliferation, 
migration and the ability to form tubes from endothelial cells and is down-regulated by 
serum and bFGF. It was observed that the overexpression of miR-21 decreases Ras 
Homolog Family Member B (RhoB) expression and activity, which appears to be 
associated with migration and tubulogenesis of endothelial cells (131).  
miR-21 is activated by asymmetric dimethylarginine (ADMA), which interferes 
with angiogenesis by direct inhibition of eNOS, causes dysfunction in the circulation of 
angiogenic progenitor cells (APCs), represses the expression of superoxide dismutase 2, 
a key enzyme in the defense of oxidative stress, and inhibit SPRY2, causing MAP 
kinase ERK activation, resulting in the decrease of NO availability and APC 
dysfunction (132). After angioplasty, in the vascular wall, there is a significant increase 
in miR-21 that partially reduces the expression of Phosphatase and tensin homolog 
(PTEN), a phosphatidylinositol 3,4,5-trisphosphate (PIP3) enzyme that inhibits the 
PI3K pathway by dephosphorylating PIP3 and consequently prevents the activation of 
AKT (133) and increases the expression of B-cell lymphoma 2 (Bcl-2) (134). Inhibition 
of miR-21 has a negative effect on neointima formation on vascular injury after 
angioplasty, decreasing cell proliferation and increasing apoptosis (134).They favor the 
proliferation of SMCs in culture, inhibiting p27 (Kip1) and p57 (Kip2), which are cell 
cycle inhibitors, and are upregulated in rat carotid arteries after angioplasty and in 
smooth muscle cells after vascular wall injury (135, 136). Besides that, it was verified 
that miR-222 acts by suppressing the expression of miR-221 (135). The treatment of 
VSMC with platelet-derived growth factor (PDGF) increased miR-221 transcription 
proving to be critical for the de-differentiation of VSMC, a characteristic of intimal 
hyperplasia, and caused a decrease in c-kit, a critical gene for the expression of 
Myocardin (Myocd) and activation of genes in VSMC, modulating the contractile 
phenotype of these cells. In this study, miR-221 acts via p27 (Kip1) (136). 
During aging, there is a progressive increase in the expression of miR-217 in 
endothelial cells in the same time there is a decrease in the expression of SirT1 (silent 
information regulator 1), a NAD-dependent deacetylease that controls transcription 
factors such as FoxO1 (forkhead Transcription factor), p53 and PGC-1a (peroxisome 
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proliferators activated receptor gamma coactivator-1a). SirT1 is involved in 
angiogenesis, longevity and resistance to diseases. It was verified that this miRNA 
represses the expression of SirT1 blocking the angiogenesis. Another miRNA, miR-34a 
is also related to the control of senescence (137). 
miR-29b is the main regulator of several genes related to collagen synthesis 
besides others related to the production of extracellular matrix which are determinants 
in renal injury, its suppression causes the increase of the expression of different types of 
collagens in the renal cortex causing fibrosis of the renal marrow (138). In the heart, the 
inhibition of miR-29b is associated with cardiac fibrosis and its increased expression 
inhibits this phenotype. The decreased in the expression of this miRNA is induced by 
angiotensin II via TGF-β/Smad3 (139). 
As exemplified above, miRNAs play a central role in the fine regulation of the 
RAAS pathway and when expressed in abnormal conditions can cause a number of 
cardiovascular effects associated with hypertension. 
2. Sympathetic 
 
 
Renal sympathetic activity appears to be essential in maintaining hypertension. 
Genetically hypertensive mice (BPH/2J) show hyperactivity of the SNS and exacerbate 
differences in BP during the day and night periods are associated with a greater 
neuronal activity. Jackson et al. demonstrated that acute sympathetic ganglion blockade 
with ACE inhibition by enalapril resulted in greater BP declines in BPH/2J animals 
when compared to normotensive animals, and thus BPH/2J mice presented a 
sympathetic contribution of up to 4 fold in the elevation of BP. In these animals, renal 
renin mRNA levels are upregulated and appear to be regulated by miR-181a, which is 
found to be lower in BPH/2J animals when compared to normotensive animals (140). 
After bilateral renal denervation, BPH animals show a greater drop in BP after 
administration of enalapril, lower levels of miR-181a and greater renin expression 
compared to normotensive animals (141). 
Dorr et al. evaluated the effects of renal sympathetic denervation on serum levels 
of miR-133a. They found elevated levels of miR-133a in the plasma of hypertensive 
patients 6 months after renal sympathetic denervation demonstrating a correlation 
between systolic blood pressure and the renal sympathetic nervous system (142). 
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3. Adipokines  
 
To date, few miRNAS have been associated with hypertension regulation 
through the adipokine pathway in humans, also correlated with obesity and diabetes. 
Recently, miR-199a-3p expression has been found to increase during adipocyte cell 
differentiation and is upregulated in obese individuals. The regulation is mediated by 
adipokines (leptin, TNF-α, and IL-β increase expression, while resistin decreases 
expression) in mature adipocytes. This miRNA possesses as possible NLK (nemo-like 
kinase), VAMP3 (vesicle-associated membrane protein 3) and Cdk7 (cyclin-dependent 
kinase 7) targets. Thus, it is speculated that this miRNA is related to the modulation in 
phenotypes of insulin resistance, inflammatory response and diabetes in obese 
individuals (143). 
In a case study with diabetic patients new potential modulators for the adipokine 
pathway were discovered. Let-7a and let-7f microRNAs were downregulated and miR-
326 was upregulated. The latter possesses adiponectin, adiponectin receptor (ADIPOR) 
-1, ADIPOR-2, and APPL-1 (molecule involved in the intracellular pathway of insulin 
signaling) as possible targets. In addition, there was an inverse correlation between the 
concentration of this miRNA and adiponectin. When treated for glycemic control, 
patients present higher serum levels of let-7a and let-7f microRNAs, but no significant 
change was observed for miR-326 (144). 
In type 2 Diabetes Mellitus, miR-126 is also decreased (145). Zampetaki et al. 
demonstrated that, in Diabetes Mellitus, elevated glucose levels cause the reduction of 
miR-126 in apoptotic bodies of endothelial cells, which can cause less delivery of this 
miRNA, through these apoptotic bodies or microparticles, to the monocytes and in this 
way increase the resistance to VEGF and contribute to endothelial dysfunction (145). 
 
4. Therapies involving miRNAs 
The miRNAs are excellent candidates for therapeutic agents, since that in many 
diseases, including in hypertension, miRNA levels are altered. This therapeutic tool can 
be used to re-establish levels of a miRNA and therefore the lost function as 
demonstrated by Zhang et al. (2014) in which the administration of miR-29b in animal 
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model of angiotensin II-induced hypertension blocks progressive heart injury 
demonstrating its function in chronic coronary disease protection (139). 
In recent years, the most used strategy is to inhibit inappropriate expression of 
an altered miRNA (146). For this to happen, chemically modified oligonucleotides, 
called antagomirs or anti-miRs, were developed which are administered intravenously 
and are capable of silencing specific endogenous microRNAs (101).  
Nevertheless, we still encounter problems regarding the delivery of these 
oligonucleotides, since a single miRNAs can interact with several RNAs and, depending 
on the mode of delivery, on different cell types (147). For example, systemic 
administration of anti-miR and anti-miR-21 blocked the development of cardiac fibrosis 
but it was also reported to have effects on the development of renal and pulmonary 
fibrosis (101). To avoid this situation and increase the efficacy of anti-miRs delivery, 
various delivery modes of such anti-miRs are being tested, though viral carriers such as 
plasmids, adenovirus, adeno-associated virus, retrovirus and lentivirus, or nonviral 
vehicles, of which we can highlight the liposomal delivery system, which is a lipid-
based nanoparticle (148), such as cholesterol or conjugated to gold nanoparticles, for 
example (101, 146). 
Recently novel classes of miRNA inhibitors are being produced, such as locked-
nucleic-acid (LNA), which exhibits greater stability and prolonged storage inside cells 
by adding a methylene bridge between the 2'-O and the 4'- C atoms in the ribose ring 
(123); and the artificial sponges of miRNAs, which are produced from transgenes 
within cells, and bind to miRNA production sites, blocking the transcription of the 
entire miRNA family (101). 
The miRNAs have great potential as biomarkers of innumerous diseases. The 
miRNAs express a reproducible pattern in biological fluids in hypertensive patients (95, 
123) and are easily isolated from plasma, urine, saliva and amniotic fluid (95) without 
suffering enzymatic degradations and changes due to changes in temperature and pH 
(102). 
 
[FIGURE 12] 
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CONCLUDING REMARKS AND FUTURE DIRECTIONS 
This review aimed to compile the knowledge generated by basic and applied 
sciences mainly regarding microRNA studies. These may help health professionals 
improve diagnostic and therapeutic accuracy, reducing mortality and morbidity in RH. 
Epigenetic as well as genetic factors are identified every day and they are 
associated with variation in blood pressure levels. As reviewed herein, mutation-
polymorphism in some signaling pathway gene may increase or decrease the expression 
of some microRNAs which are involved both in RH development, therapy response as 
RH associated complications such as renal failure, coronary artery disease, cardiac 
hypertrophy, stroke among others. Therefore, the use of microRNA as biomarkers in 
prevention, diagnosis and therapy of this disease, may help to understand the disease, 
improve pharmacology therapy as well prevent complications.  
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Figure Legends 
 
FIGURE 1: Recommendations for Diagnostics of RH.  ABPM:  Ambulatory Blood 
Pressure  Monitoring; BP: Blood Pressure; RH: Resistant Hypertension; WCH: White-
Coat Hypertension. Modified Calhoun (1) and Passarelli, Gonçalves (16) 
 
FIGURE 2: Hemodynamic control of Renin-Angiotensin-Aldosterone System. ACE: 
Angiotensin Converting Enzyme;  Modified Maron and Leopold (18) 
FIGURE 3: Signaling pathway Na
+/
k
+
-ATPase activity and Aldosterone. 
FIGURE 4: Signalling pathway involved in Primary Aldosteronism. S1P – 
Sphingosine-1-phosphate; HB-EGF – Heparin biding-Epidermal growth factor; EGFR – 
Epidermal growth factor receptor; GPCR – G protein coupled receptor; PLD – 
Phospholipase; PKC – Protein kinase C; PI3K –Phosphoinositide 3 kinase; PIP2 – 
Phosphatidylinositol 4,5-biphosphate; PIP3 – Phosphatidylinositol (3,4,5)-triphosphate; 
AKT – Protein kinase B; mTOR – Mammalian target of rapamycin; MEK – mitogen-
activated protein kinase; ERK – extracellular regulated kinase. 
FIGURE 5: Signaling pathway of the SRAA axis. The figure show the regulate 
processes for the Ang-(1-7)/Mas in different signaling pathways, compere to the 
opposes RAAS classical axes of this system, the ACE/AngII/AT1R. ANG-(1-7) – 
Angiotensin-(1-7); GPCR – G protein coupled receptor; PLC – Phospholipase C; DAG 
– Diacylglycerol; IP3 – Inositol triphosphate; PKC – Protein kinase C; PI3K – 
Phosphoinositide 3 kinase; PIP2 – Phosphatidylinositol 4,5-biphosphate; PIP3 – 
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Phosphatidylinositol (3,4,5)-triphosphate; AKT – Protein kinase B; NO – Nitric Oxide; 
COX-2 – Cyclooxygenase-2; PG – Prostaglandin; ERK – extracellular regulated kinase. 
FIGURE 6:  Signaling Leptin pathway. The figure outlines the relationship between 
Leptin and mechanisms involved in the neurons signaling as stimulates the sympathetic 
nervous system, processes involved in pathogenesis of hypertension link to obesity. 
SNS: Sympathetic Nervous System; RAS: Renin-Angiotensin System; FFA: Free Fatty 
Acids; NO: Nitric Oxide. Modified Rahmouni (51) 
FIGURE 7: CAV1 Signaling Pathway. The stimulate of tyrosine kinase insulin 
receptor CAV1 signaling pathway lead activate PI3K resulting in translocation of the 
vesicle and exhibition of the GLUT4 in cell membrane. CAV1 – caveolin-1; GM3 – 
ganglioside; IRS-1 – insulin receptor substrate 1; PI3K –Phosphoinositide 3 
kinase;PDK - Phosphoinositide-dependent kinase-1; AKT - Akt/protein kinase B; PIP2 
– Phosphatidylinositol 4,5-biphosphate; PIP3 – Phosphatidylinositol (3,4,5)-
triphosphate; GLUT4 – glucose transporter 4. AS160 - Akt substrate of 160 kDa. 
 
FIGURE 8: Signaling pathways involved in the development and progression of 
RH. The figure illustrates the existing relationship between cell signaling mechanisms 
involved in the pathogenesis of hypertension.  AGII – Angiotensin II; ET1 – Endothelin 
1; S1P – Sphingosine-1-phosphate; NOX1 – NADPH oxidase 1; ROS – Reactive 
oxygen species; MMP – Matrix Metalloproteinase; HB-EGF – Heparin biding-
Epidermal growth factor; ANG-(1-7) – Angiotensin-(1-7); GPCR – G protein coupled 
receptor;; PLA2 – Phospholipase A2; PLC – Phospholipase C; AA – Arachidonic Acid; 
CYP4A – Cytochrome P450-4A; MAPK – Mitogen-activated protein kinase; NO – 
Nitric oxide; PLD – Phospholipase; DAG – Diacylglycerol; IP3 – Inositol triphosphate; 
PKC – Protein kinase C; PI3K –Phosphoinositide 3 kinase; PIP2 – Phosphatidylinositol 
4,5-biphosphate; PIP3 – Phosphatidylinositol (3,4,5)-triphosphate; AKT – Protein 
kinase B; mTOR – Mammalian target of rapamycin; COX-2 – Cyclooxygenase-2; PG – 
Prostaglandin; MEK – mitogen-activated protein kinase; ERK – extracellular regulated 
kinase; IR – insulin receptor; CAV1 – caveolin-1. 
FIGURE 9: EGFR Signaling Pathway in vascular smooth muscle. The agonist 
action of the GPCR receptors stimulates NOX1 phatway lead to the increase of the 
oxidative stress NOX1which the activating  the signaling pathway of the EGFR.  – 
NADPH oxidase 1; ROS – Reactive oxygen species; MMP – Matrix Metalloproteinase; 
HB-EGF – Heparin biding-Epidermal growth factor; EGFR – Epidermal growth factor 
receptor; GPCR – G protein coupled receptor; PLC – Phospholipase C; DAG – 
Diacylglycerol; IP3 – Inositol triphosphate; PKC – Protein kinase C; PI3K –
Phosphoinositide 3 kinase; PIP2 – Phosphatidylinositol 4,5-biphosphate; PIP3 – 
Phosphatidylinositol (3,4,5)-triphosphate; AKT – Protein kinase B; mTOR – 
Mammalian target of rapamycin. 
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FIGURE 10: Ang II stimulates signaling pathway through 20-HETE. The stimulate 
of GPCR by AngII agonist activate PLA2 which shoots the signaling intracellular 
phathway leading activation of PKC as release calcium influx.  ROS – Reactive oxygen 
species; GPCR – G protein coupled receptor; PLA2 – Phospholipase A2; CYP4A – 
Cytochrome P450-4A; COX – Cyclooxygenase; LO – Lipoxygenase ; LTs – 
Leukotrienes; 20-HETE – 20-hydroxyeicosatetraenoic acid; PGE2 – Prostaglandin E2; 
PGI2 – Prostacyclin; PGH2 – Prostaglandin H2; TXA2 – Tromboxane A2; MAPK – 
Mitogen-activated protein kinase; NO – Nitric oxide;  
FIGURE 11: Biogenesis of miRNAs in mammals. 1. miRNAs are transcripted in the 
nucleus by RNA polymerase II from long precursors. 2. In the nucleus they are 
processed by a complex formed by Drosha and its cofactor DGCR8. 3. 3. The pre-
miRNAs are transported to the cytoplasm by the Exportin-5 receptor. 4. In the 
cytoplasm, the pre-miRNAs are processed by Dicer resulting in the formation of 
miRNA:miRNA duplex 5. The miRNA:miRNA duplex is processed by helicase 6. 
Association with RISC complex. 7. Repression or inhibition of mRNA. 
 
 
FIGURE 12. Scheme of miRNA pathway in Hypertension. Scheme of miRNA 
pathway in Hypertension. Major microRNAs involved in the hypertension pathogenesis. 
In red, those that act on muscle cells; In green, those presents on cardiomyocytes; In 
blue, those that are expressed in endothelial cells; In brown, those that act on 
fibroblasts; In purple, present in renal cells; in yellow, those that are expressed in 
adipocytes; In black, the present in plasma. NO – Nitric Oxide; ERK – extracellular 
regulated kinase, GATA2 - Endothelial transcription factor GATA2; PAK4 - 
Serine/threonine-protein kinase PAK4; CYP11B1 - 11β-hydroxylase CYP11B2 - 
aldosterone synthase; Sprouty-related protein (Spred-1); Vascular Smooth Muscle Cells 
(VSMCs); C-X-C motif ligand 12 - CXCL12; nuclear receptor of subfamily 3 group C 
member 2 - NR3C2; monocyte chemoattractant protein-1 -MCP-1; Angiotensin type 2 
receptor - AT2R; Cyclin-dependent kinase inhibitor 1B - p27, Kip1; Cyclin-dependent 
kinase inhibitor 1C -p57, Kip2; Vascular Endothelial Growth Factor (VEGF); Vascular 
Cell Adhesion Molecule 1 (VCAM-1); Ras Homolog Family Member B (RhoB), 
Phosphoinositide-3-kinase regulatory subunit 2 (PIK3R2); Phosphatase and tensin 
homolog (PTEN); Protein sprouty homolog 2 (Sprouty-2); Angiotensin-Converting 
Enzyme (ACE); ; Silent information regulator 1 (SirT1); Angiotensin II Receptor 
(AT1R); Angiotensinogen (AGT); arginine-vasopressin receptor (AVPR1A); 
bradykinin β2 receptor (BDKRB2); thromboxane A2 receptor (TBXA2R); B-cell 
lymphoma 2 (Bcl-2) 
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AKT – Protein kinase B; mTOR – Mammalian target of rapamycin; MEK – mitogen-
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opposes RAAS classical axes of this system, the ACE/AngII/AT1R. ANG-(1-7) – 
Angiotensin-(1-7); GPCR – G protein coupled receptor; PLC – Phospholipase C; DAG 
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Prostaglandin; MEK – mitogen-activated protein kinase; ERK – extracellular regulated 
kinase; IR – insulin receptor; CAV1 – caveolin-1. 
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TABLE 1: Forms of Secondary Hypertension Associated with RH. Modified Vongpatanasin (14) 
Conditions 
Obstructive Sleep 
Apnea 
Primary Aldoteronism Renal Artery Stenosis 
 
Renal 
Parenchyma 
Disease 
Use of drugs 
and alcohol 
Thyroid 
Disorders 
Diagnostic 
Tests 
 
Polysomnography 
Serum aldosterone, 
plasma renin 
activity 
Duplex Doppler 
ultrasonography, 
Computedtomographic 
angiography, or magnetic 
resonance angiography 
Serum creatinine History taking 
Thyrotropin, 
free thyroxine 
Treatment 
Continuous 
positive airway 
Pressure 
Spironolactone, 
eplerenone, orsurgical 
resection of tumor 
inunilateral aldosterone-
producing 
Adenoma 
Renal revascularization 
in selected patients 
Correction of 
underlying causes 
if possible 
Discontinuatio
n of 
offendingagent
s 
According to 
underlying 
disorders 
Prevalence in 
RH (%) 
60-70 7-20 2-24 1-2 2-4 <1 
References (7, 149, 150) (8, 9, 151-154) (7, 155-157) (1, 7) (1, 7, 158) (1, 7) 
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Table 2. miRNAs related to hypertension 
MiRNA Cells Type Target Referen
ces 
miR-126 Endothelial apoptotic bodies 
Endothelial cells 
Endothelial apoptotic bodies 
Plasma 
Zebrafish embryos 
Endothelial cells 
Peripheral blood 
mononuclear cells 
Mouse Endothelial cells 
VEGF 
VCAM-1 
SPRED-1 and PIK3R2 
(127-
129, 138, 
145) 
miR-21 Endothelial cells 
Angiogenic progenitor cells 
Rat vascular smooth muscle 
cells 
Murine hearts 
Vascular smooth muscle 
cells 
RhoB 
Superoxide dismutase 2 
Sprouty-2 
PTEN 
Bcl-2 
 
(130-
134) 
miR-143 and 
miR-145 
Mice/Rat/Mouse VSMCs ACE 
Modulators of SRF 
activity 
(121-
124) 
miR-221 and 
miR-222 
Rat VSMCs p27 (Kip1) 
p57 (Kip2) 
c-Kit 
(135-
136) 
 
miR-217 Human umbilical vein 
endothelial cells 
Human aortic endothelial 
cells 
SirT1 (137) 
 
Human coronary artery 
endothelial cells 
miR-9 Rats Cardiomyocytes 
PBMCs 
Myocardin (125-
126) 
miR-155 and 
miR-802 
CHO cells 
C2BBe1 cell line 
Rat aortic adventitial 
fibroblasts 
AT1R (106-
108) 
miR-296-5p, 
let-7e, hcmv-
miR-UL112 
and hcmv-
miR-UL1 
Plasma IRF-1 
MICB 
(109) 
miR-483-3p HEK-AT1R 
HEK-AT2R 
HASMC 
HL1-AT1R 
RASMC 
RASMC-AT1R 
RASMC-AT2R 
Whole heart (C3H NT) 
Whole heart (C3H TG) 
Whole heart 
(C57BL/6 NT) 
Whole heart 
(C57BL/6 TG) 
AGT 
ECA-1 
ECA2 
AT2R 
(110) 
miR-122 Plasma 
Mouse Endothelial Cells 
rs41318021 
polymorphism in the 
SLC7A1 gene 
3´UTR of the L-Arginine 
Transporter Gene 
(113-
115) 
SLC7A1 
miR-24 Cardiac endothelial cells 
Mouse Endothelial cells, 
cardiomyocytes and cardiac 
fibroblasts 
HUVECs and HMVECs 
Human adrenocortical cell 
line 
GATA2 
PAK4 
CYP11B1 
CYP11B2 
(116-
118) 
miR-124 and 
miR-135a 
Study In silico Mineralocorticoid 
receptor NR3C2 
(119) 
miR-526b, 
miR-578, 
miR-34a, 
miR-34c, 
miR-765 
mir-153-3p 
and miR-383 
Study of Myocardial 
Infarctions Leiden 
Four SNPs located in the 
arginine vasopressin 1A 
receptor, bradykinin 2 
receptor and 
thromboxane A2 receptor 
(112) 
miR-584 and 
miR-31 
Hep3B cells 
HEK293 cells 
Genetically hypertensive 
mice (BPH/2J) 
Polymorphism at 11525C 
in hAGT 3′-UTR 
 
(120, 
140, 
141) 
miR-181a 
and miR-663 
HEK293 cells 
Plasma 
Renin (104-
105) 
miR-29b Mouse heart 
Cardiac fibroblastos 
Rat renal medullary 
epithelial cells 
TGF-β1 
Collagen genes 
 
(138-
139) 
miR-132 and 
miR-212 
 
Rat heart, aorta and kidney 
Rat Plasma 
AT1R 
 
(111) 
Human artery 
 miR-199a-
3p 
Adipocytes  NLK 
VAMP3  
Cdk7  
(143) 
miR-326 Plasm  ADIPOR-1 
ADIPOR-2 
APPL-1  
(144) 
miR-133a Plasm - (142) 
Sprouty-related protein (Spred-1); Vascular Smooth Muscle Cells (VSMCs); Vascular 
Endothelial Growth Factor (VEGF); Vascular Cell Adhesion Molecule 1 (VCAM-1); 
Phosphoinositide-3-kinase regulatory subunit 2 (PIK3R2); Phosphatase and tensin 
homolog (PTEN); Ras Homolog Family Member B (RhoB); Protein sprouty homolog 2 
(Sprouty-2); Angiotensin-Converting Enzyme (ACE); Serum Response Factor (SRF); 
Silent information regulator 1 (SirT1); Angiotensin II Receptor (AT1R); Transforming 
Growth Factor (TGF)-β1; Angiotensinogen (AGT); nemo-like kinase (NLK); vesicle 
associated membrane protein 3 (VAMP3); cyclin-dependent kinase 7 (Cdk7); 
adiponectin receptor 1(ADIPOR-1); adiponectin receptor 2 (ADIPOR-2); Adaptor 
protein, phosphotyrosine interacting with PH domain and leucine zipper 1 (APPL-1) 
 
 
 













